Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia

Pyung Chun Oh, Kwang Kon Koh, Ichiro Sakuma, Soo Lim, Yonghee Lee, Seungik Lee, Kyounghoon Lee, Seung Hwan Han, Eak Kyun Shin

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background Experimental studies demonstrate that higher intake of omega-3 fatty acids (n - 3 FA) improves insulin sensitivity, however, we reported that n - 3 FA 2 g therapy, most commonly used dosage did not significantly improve insulin sensitivity despite reducing triglycerides by 21% in patients. Therefore, we investigated the effects of different dosages of n - 3 FA in patients with hypertriglyceridemia.

Methods This was a randomized, single-blind, placebo-controlled, parallel study. Age, sex, and body mass index were matched among groups. All patients were recommended to maintain a low fat diet. Forty-four patients (about 18 had metabolic syndrome/type 2 diabetes mellitus) in each group were given placebo, n - 3 FA 1 (O1), 2 (O2), or 4 g (O4), respectively daily for 2 months.

Results n - 3 FA therapy dose-dependently and significantly decreased triglycerides and triglycerides/HDL cholesterol and improved flow-mediated dilation, compared with placebo (by ANOVA). However, each n - 3 FA therapy did not significantly decrease high-sensitivity C-reactive protein and fibrinogen, compared with placebo. O1 significantly increased insulin levels and decreased insulin sensitivity (determined by QUICKI) and O2 significantly decreased plasma adiponectin levels relative to baseline measurements. Of note, when compared with placebo, each n - 3 FA therapy did not significantly change insulin, glucose, adiponectin, glycated hemoglobin levels and insulin sensitivity (by ANOVA). We observed similar results in a subgroup of patients with the metabolic syndrome.

Conclusions n - 3 FA therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation. Nonetheless, n - 3 FA therapy did not significantly improve acute-phase reactants and insulin sensitivity in patients with hypertriglyceridemia, regardless of dosages.

Original languageEnglish
Pages (from-to)696-702
Number of pages7
JournalInternational Journal of Cardiology
Volume176
Issue number3
DOIs
StatePublished - 20 Oct 2014

Fingerprint

Hypertriglyceridemia
Omega-3 Fatty Acids
Insulin Resistance
Dilatation
Triglycerides
Placebos
Adiponectin
Analysis of Variance
Therapeutics
Insulin
Fat-Restricted Diet
Acute-Phase Proteins
Glycosylated Hemoglobin A
C-Reactive Protein
Fibrinogen
Type 2 Diabetes Mellitus
HDL Cholesterol
Body Mass Index
Research Design
Glucose

Keywords

  • Atherosclerosis
  • Hypertriglyceridemia
  • Insulin resistance
  • Omega-3 fatty acids

Cite this

Oh, Pyung Chun ; Koh, Kwang Kon ; Sakuma, Ichiro ; Lim, Soo ; Lee, Yonghee ; Lee, Seungik ; Lee, Kyounghoon ; Han, Seung Hwan ; Shin, Eak Kyun. / Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia. In: International Journal of Cardiology. 2014 ; Vol. 176, No. 3. pp. 696-702.
@article{c6a92042d12c48528462738a5c38ffcf,
title = "Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia",
abstract = "Background Experimental studies demonstrate that higher intake of omega-3 fatty acids (n - 3 FA) improves insulin sensitivity, however, we reported that n - 3 FA 2 g therapy, most commonly used dosage did not significantly improve insulin sensitivity despite reducing triglycerides by 21{\%} in patients. Therefore, we investigated the effects of different dosages of n - 3 FA in patients with hypertriglyceridemia.Methods This was a randomized, single-blind, placebo-controlled, parallel study. Age, sex, and body mass index were matched among groups. All patients were recommended to maintain a low fat diet. Forty-four patients (about 18 had metabolic syndrome/type 2 diabetes mellitus) in each group were given placebo, n - 3 FA 1 (O1), 2 (O2), or 4 g (O4), respectively daily for 2 months.Results n - 3 FA therapy dose-dependently and significantly decreased triglycerides and triglycerides/HDL cholesterol and improved flow-mediated dilation, compared with placebo (by ANOVA). However, each n - 3 FA therapy did not significantly decrease high-sensitivity C-reactive protein and fibrinogen, compared with placebo. O1 significantly increased insulin levels and decreased insulin sensitivity (determined by QUICKI) and O2 significantly decreased plasma adiponectin levels relative to baseline measurements. Of note, when compared with placebo, each n - 3 FA therapy did not significantly change insulin, glucose, adiponectin, glycated hemoglobin levels and insulin sensitivity (by ANOVA). We observed similar results in a subgroup of patients with the metabolic syndrome.Conclusions n - 3 FA therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation. Nonetheless, n - 3 FA therapy did not significantly improve acute-phase reactants and insulin sensitivity in patients with hypertriglyceridemia, regardless of dosages.",
keywords = "Atherosclerosis, Hypertriglyceridemia, Insulin resistance, Omega-3 fatty acids",
author = "Oh, {Pyung Chun} and Koh, {Kwang Kon} and Ichiro Sakuma and Soo Lim and Yonghee Lee and Seungik Lee and Kyounghoon Lee and Han, {Seung Hwan} and Shin, {Eak Kyun}",
year = "2014",
month = "10",
day = "20",
doi = "10.1016/j.ijcard.2014.07.075",
language = "English",
volume = "176",
pages = "696--702",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia. / Oh, Pyung Chun; Koh, Kwang Kon; Sakuma, Ichiro; Lim, Soo; Lee, Yonghee; Lee, Seungik; Lee, Kyounghoon; Han, Seung Hwan; Shin, Eak Kyun.

In: International Journal of Cardiology, Vol. 176, No. 3, 20.10.2014, p. 696-702.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia

AU - Oh, Pyung Chun

AU - Koh, Kwang Kon

AU - Sakuma, Ichiro

AU - Lim, Soo

AU - Lee, Yonghee

AU - Lee, Seungik

AU - Lee, Kyounghoon

AU - Han, Seung Hwan

AU - Shin, Eak Kyun

PY - 2014/10/20

Y1 - 2014/10/20

N2 - Background Experimental studies demonstrate that higher intake of omega-3 fatty acids (n - 3 FA) improves insulin sensitivity, however, we reported that n - 3 FA 2 g therapy, most commonly used dosage did not significantly improve insulin sensitivity despite reducing triglycerides by 21% in patients. Therefore, we investigated the effects of different dosages of n - 3 FA in patients with hypertriglyceridemia.Methods This was a randomized, single-blind, placebo-controlled, parallel study. Age, sex, and body mass index were matched among groups. All patients were recommended to maintain a low fat diet. Forty-four patients (about 18 had metabolic syndrome/type 2 diabetes mellitus) in each group were given placebo, n - 3 FA 1 (O1), 2 (O2), or 4 g (O4), respectively daily for 2 months.Results n - 3 FA therapy dose-dependently and significantly decreased triglycerides and triglycerides/HDL cholesterol and improved flow-mediated dilation, compared with placebo (by ANOVA). However, each n - 3 FA therapy did not significantly decrease high-sensitivity C-reactive protein and fibrinogen, compared with placebo. O1 significantly increased insulin levels and decreased insulin sensitivity (determined by QUICKI) and O2 significantly decreased plasma adiponectin levels relative to baseline measurements. Of note, when compared with placebo, each n - 3 FA therapy did not significantly change insulin, glucose, adiponectin, glycated hemoglobin levels and insulin sensitivity (by ANOVA). We observed similar results in a subgroup of patients with the metabolic syndrome.Conclusions n - 3 FA therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation. Nonetheless, n - 3 FA therapy did not significantly improve acute-phase reactants and insulin sensitivity in patients with hypertriglyceridemia, regardless of dosages.

AB - Background Experimental studies demonstrate that higher intake of omega-3 fatty acids (n - 3 FA) improves insulin sensitivity, however, we reported that n - 3 FA 2 g therapy, most commonly used dosage did not significantly improve insulin sensitivity despite reducing triglycerides by 21% in patients. Therefore, we investigated the effects of different dosages of n - 3 FA in patients with hypertriglyceridemia.Methods This was a randomized, single-blind, placebo-controlled, parallel study. Age, sex, and body mass index were matched among groups. All patients were recommended to maintain a low fat diet. Forty-four patients (about 18 had metabolic syndrome/type 2 diabetes mellitus) in each group were given placebo, n - 3 FA 1 (O1), 2 (O2), or 4 g (O4), respectively daily for 2 months.Results n - 3 FA therapy dose-dependently and significantly decreased triglycerides and triglycerides/HDL cholesterol and improved flow-mediated dilation, compared with placebo (by ANOVA). However, each n - 3 FA therapy did not significantly decrease high-sensitivity C-reactive protein and fibrinogen, compared with placebo. O1 significantly increased insulin levels and decreased insulin sensitivity (determined by QUICKI) and O2 significantly decreased plasma adiponectin levels relative to baseline measurements. Of note, when compared with placebo, each n - 3 FA therapy did not significantly change insulin, glucose, adiponectin, glycated hemoglobin levels and insulin sensitivity (by ANOVA). We observed similar results in a subgroup of patients with the metabolic syndrome.Conclusions n - 3 FA therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation. Nonetheless, n - 3 FA therapy did not significantly improve acute-phase reactants and insulin sensitivity in patients with hypertriglyceridemia, regardless of dosages.

KW - Atherosclerosis

KW - Hypertriglyceridemia

KW - Insulin resistance

KW - Omega-3 fatty acids

UR - http://www.scopus.com/inward/record.url?scp=84908256265&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2014.07.075

DO - 10.1016/j.ijcard.2014.07.075

M3 - Article

C2 - 25147070

AN - SCOPUS:84908256265

VL - 176

SP - 696

EP - 702

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 3

ER -